This bill would create a new article in the Public Health Law establishing a statewide framework for regenerative medicine and cell-based therapies, and it would also amend the Education Law and add a facility-policy requirement in the Public Health Law. The measure is titled the “New York regenerative medicine advancement and patient protection act” and is designed to allow physicians to provide qualifying regenerative medicine protocols while setting conditions for lawful practice, sourcing, disclosure, advertising, reporting, and enforcement.
The bill defines regenerative medicine broadly to include cell-based and tissue-based therapies, orthobiologics, and other human cells, tissues, and cellular and tissue-based products. It permits physicians to perform qualifying protocols if they are within scope of practice, performed in authorized settings, use federally compliant products, and are not prohibited by federal law. It also requires product traceability and documentation, including source, chain of custody, and accreditation where applicable, and it directs the Department of Health to establish a statewide registry, collect de-identified utilization and adverse-event data, and publish annual reports.
The bill places significant patient-protection requirements on informed consent and advertising. Before using a product or protocol not approved, licensed, or cleared by the FDA for the specific indication, physicians must obtain written informed consent in plain language that explains the treatment’s status, risks, alternatives, expected costs, and the fact that outcomes are not guaranteed. Advertising must not be false, misleading, deceptive, or unsubstantiated, and ads for non-FDA-approved uses must include a conspicuous notice warning patients and encouraging consultation with a primary care provider or specialist.
The bill would also create an innovation program within the Department of Health, in consultation with other state agencies, to promote New York as a center for regenerative medicine research, manufacturing, and clinical excellence. It authorizes rulemaking, civil penalties for knowing violations, misdemeanor liability for falsifying registry data or concealing adverse events, and it amends the Education Law to make violations of the new article professional misconduct. Hospitals, ambulatory surgery centers, and diagnostic and treatment centers offering these services would have to adopt written policies on credentialing, patient selection, informed consent, adverse-event review, and compliance.
The overall sentiment reflected in the bill text is strongly supportive of regenerative medicine, but with a clear emphasis on consumer protection, transparency, and regulatory oversight. Because there are no committee transcripts or recorded votes provided, there is no documented opposition or debate in the available materials. The main likely points of contention are the scope of permissible regenerative medicine practices, the treatment of non-FDA-approved or investigational therapies, the advertising restrictions, and the reporting and enforcement obligations imposed on physicians and facilities.
The bill would add a new regulatory structure to the Public Health Law governing regenerative medicine and cell-based therapies, while also creating a new professional misconduct basis in the Education Law for violations of the framework. It would require physicians and facilities to comply with sourcing, documentation, informed-consent, advertising, registry reporting, and adverse-event reporting rules, and it would authorize the Department of Health to promulgate implementing regulations, enforce the article, and assess civil penalties. Hospitals and other licensed facilities offering these services would also need written internal policies addressing compliance and patient safety.
The bill’s tone is generally pro-innovation and pro-access, but it is paired with strong patient-protection language. The text frames regenerative medicine as a promising field that New York should help lead, while repeatedly emphasizing ethical sourcing, truthful advertising, informed consent, and safety monitoring. No committee discussion or vote history is available, so there is no recorded public sentiment beyond the bill’s own stated policy goals.
The most notable areas of potential contention are the bill’s treatment of therapies that are not FDA-approved for a specific indication, the limits it places on advertising and efficacy claims, and the compliance burden created by registry reporting and adverse-event reporting. Physicians, clinics, and manufacturers may view the framework as either a needed legal pathway or an added regulatory hurdle, while patient advocates and regulators are likely to focus on whether the bill sufficiently prevents deceptive marketing, unsafe products, and unethical tissue sourcing. The bill also explicitly bars tissue derived from abortion procedures, which could be a separate point of ethical and political disagreement.